Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
541-560 of 998 trials

Amyotrophic Lateral Sclerosis: ARGX-119 Study

We are testing a new treatment called ARGX-119 for adults with ALS to see if it is safe and how well it works in slowing disease progression.

Amyotrophic Lateral Sclerosis (ALS)>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Advanced Non-Small Cell Lung Cancer: BAY 2927088 Study

We are investigating how well BAY 2927088 works and its safety compared to standard treatment for patients with advanced non-small cell lung cancer with HER2 mutations.

Advanced Non-Small Cell Lung Cancer with HER2 MutationConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Oral Propranolol for Preventing Eye Issues in Premature Infants

We are studying whether oral propranolol can help extremely preterm infants lower their risk of developing threshold retinopathy of prematurity. This research aims to improve safety and reduce the need for additional treatments.

Retinopathy of Prematurity>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteOphthalmologyPediatrics

Crohn's Disease: EXL01 for Post-Surgery Recurrence Prevention

We are studying whether EXL01 can help prevent the return of Crohn's disease in patients after surgery. This trial compares its effects to a placebo to assess safety and effectiveness.

Crohn's Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteGastroenterologyInternal Medicine

Sasanlimab for Muscle Invasive Bladder Cancer

We are studying whether sasanlimab can help patients with muscle invasive bladder cancer keep their bladder intact after initial treatment. The trial looks at survival rates and quality of life for participants.

Invasive Bladder Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Colchicine for Knee and Hip Osteoarthritis

We are studying whether colchicine can help reduce the need for knee or hip replacements in people with osteoarthritis. The trial also looks at its effects on pain, physical function, and overall quality of life.

Osteoarthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyRheumatology

Ulcerative Colitis: Filgotinib for Kids and Teens

We are studying the effects of filgotinib in children and teenagers with moderately to severely active ulcerative colitis. The trial aims to see if it helps achieve remission and improves quality of life.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Fibrodysplasia Ossificans Progressiva: Fidrisertib Study

We are studying a new oral medication for people with fibrodysplasia ossificans progressiva to see if it can help prevent new bone growth and improve overall health. This trial includes both children and adults to evaluate its safety and effectiveness.

Fibrodysplasia Ossificans ProgressivaEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurology

Early Rheumatoid Arthritis: Biomarker Study for Abatacept

We are investigating if certain biomarkers can predict how well patients with early rheumatoid arthritis respond to abatacept treatment. This may help tailor therapies to individual needs.

Rheumatoid Arthritis3-6 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Chronic Myeloid Leukemia: Olverembatinib Study

We are testing a new drug, Olverembatinib, for patients with Chronic Phase Chronic Myeloid Leukemia. The study aims to see if it works better than the current treatment, Bosutinib, especially for those with a specific mutation.

Chronic Myeloid Leukemia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Breast Cancer: Alisertib with Hormone Therapy

We are studying how well alisertib works with hormone therapy for patients with recurrent or metastatic hormone receptor positive, HER2 negative breast cancer. Our goal is to find the best dose and assess safety and effectiveness.

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

Fanconi Anaemia: Gene Therapy Study

We are evaluating the long-term safety and effects of a gene therapy using modified cells in patients with Fanconi Anaemia Subtype A. This study aims to understand how well the treatment works and its impact on blood health over time.

Fanconi's AnemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyInternal Medicine

HIV Research: Topiramate Treatment

We are investigating whether topiramate can help activate hidden HIV in people on antiretroviral therapy. The study also examines the safety of this medication and how various factors may influence its effects.

HIV-1 Infection≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

RECLAIM: Treatments for Long COVID

We are studying different treatments for people suffering from long COVID to see how they improve physical and mental health. The trial will also assess specific symptoms like fatigue and cognitive difficulties.

Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Prostate Cancer: PF-06821497 with Enzalutamide

We are studying a new treatment combining PF-06821497 with enzalutamide for men with advanced prostate cancer previously treated with abiraterone. The goal is to see if this combination can improve survival and reduce tumor activity compared to standard therapies.

Castration-resistant Prostate Cancer6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Long-term Safety of Genetically Modified T Cell Therapy

We are following up with patients who received genetically modified T cells to assess their long-term safety and survival. This study aims to understand how well the treatment works and any potential risks involved.

Acute Lymphoblastic LeukemiaSystemic Lupus ErythematosusNon-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncologyRheumatology

Dexamethasone for Congenital Adrenal Hyperplasia in Pregnancy

We are studying whether a lower dose of dexamethasone can effectively prevent prenatal complications in female babies with congenital adrenal hyperplasia. We will also monitor the health of mothers and their children during and after pregnancy.

Congenital Adrenal HyperplasiaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyGynecology and Obstetrics

High Blood Pressure: Irbesartan and Amlodipine Combination

We are testing a new fixed-dose pill combining irbesartan and amlodipine for patients with high blood pressure. The goal is to see if it effectively lowers blood pressure and is safe for use.

High Blood Pressure1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Stage III Lung Cancer: Surgery and Durvalumab Study

We are exploring whether surgery is safe for patients with initially unresectable stage III lung cancer after high-dose treatment. We also want to see if they can benefit from a follow-up therapy called durvalumab.

Stage III Non-Small Cell Lung CancerMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Adnexal Torsion: Contrast-Enhanced Ultrasound Study

We are testing a new ultrasound method to see if it helps diagnose adnexal torsion more accurately than standard methods. This could reduce unnecessary surgeries and improve care for patients with suspected torsion.

Adnexal Torsion>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine